CADL•benzinga•
Candel Therapeutics Final Survival Data From Randomized Controlled Phase 2 Clinical Trial CAN-2409 In Non-Metastatic Pancreatic Cancer Showing Improvement In Estimated Median Overall Survival Of 31.4 Months After Treatment vs 12.5 Months In Control Group
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga